(19)
(11) EP 4 583 980 A1

(12)

(43) Date of publication:
16.07.2025 Bulletin 2025/29

(21) Application number: 23862610.5

(22) Date of filing: 06.09.2023
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
A61K 9/08(2006.01)
C07K 16/46(2006.01)
A61K 39/395(2006.01)
C07K 16/28(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/28; A61P 35/00; A61K 9/08; A61K 9/0019; C07K 16/2809; C07K 2317/31; C07K 2317/52; C07K 2317/55; C07K 2317/90; A61K 2039/505; A61K 2039/545
(86) International application number:
PCT/IB2023/058820
(87) International publication number:
WO 2024/052831 (14.03.2024 Gazette 2024/11)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 09.09.2022 US 202263405188 P
28.10.2022 US 202263420146 P

(71) Applicant: Janssen Biotech, Inc.
Horsham, PA 19044 (US)

(72) Inventors:
  • AVADHANI, Anjali
    Raritan, New Jersey 08869 (US)
  • BASU, Subhasree
    Spring House, Pennsylvania 19477 (US)
  • JAIPRASART, Pharavee
    Spring House, Pennsylvania 19477 (US)
  • XIE, Hong
    Spring House, Pennsylvania 19477 (US)
  • YAO, David
    Chesterbrook, Pennsylvania 19087 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) METHOD OF TREATING CANCER WITH AN ANTI TMEFF2XCD3 BISPECIFIC ANTIBODY